Pavel Klener
Overview
Explore the profile of Pavel Klener including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Skrlova E, Uherkova E, Klimova A, Malarikova D, Svozilkova P, Matous P, et al.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
. 2024 Feb;
169(1):49-55.
PMID: 38410917
Aim: The purpose of this project was to compare the characteristics of two experimental murine models of primary intraocular lymphoma (PIOL) and determine which experimental model is most suitable for...
12.
Foppiani J, Raska O, Taritsa I, Hernandez Alvarez A, Lee D, Escobar-Domingo M, et al.
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203524
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a distinct subtype of T-cell non-Hodgkin lymphoma that arises in the context of prolonged exposure to textured breast implants. The intent of...
13.
Sovilj D, Kelemen C, Dvorakova S, Zobalova R, Raabova H, Kriska J, et al.
Apoptosis
. 2023 Nov;
29(3-4):424-438.
PMID: 38001340
Proteins from the Bcl-2 family play an essential role in the regulation of apoptosis. However, they also possess cell death-unrelated activities that are less well understood. This prompted us to...
14.
Patra-Kneuer M, Chang G, Xu W, Augsberger C, Grau M, Zapukhlyak M, et al.
Front Immunol
. 2023 Aug;
14:1220558.
PMID: 37600821
Background: Despite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody...
15.
Brehova P, Reznickova E, Skach K, Jorda R, Dejmek M, Vojackova V, et al.
J Med Chem
. 2023 Aug;
66(16):11133-11157.
PMID: 37535845
FLT3 kinase is a potential drug target in acute myeloid leukemia (AML). Patients with FLT3 mutations typically have higher relapse rates and worse outcomes than patients without FLT3 mutations. In...
16.
Schmitt A, Grimm M, Kreienkamp N, Junge H, Labisch J, Schuhknecht L, et al.
Blood
. 2023 Jun;
142(13):1143-1155.
PMID: 37294920
Diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, is characterized by an aggressive clinical course. In approximately one-third of patients with DLBCL, first-line multiagent immunochemotherapy fails...
17.
Sykorova A, Prochazka V, Mocikova H, Janikova A, Pytlik R, Belada D, et al.
Neoplasma
. 2023 Jan;
69(6):1466-1473.
PMID: 36591807
Burkitt lymphoma (BL) is a rare subtype of non-Hodgkin's lymphoma with an aggressive course. To refine the individual patient's prognosis, the International Prognostic Index for BL (BL-IPI) was recently developed...
18.
Tomanova M, Kozlanska K, Jorda R, Jedinak L, Havlikova T, Reznickova E, et al.
Int J Mol Sci
. 2022 Dec;
23(24).
PMID: 36555810
Therapy of FLT3-positive acute myeloid leukemia still remains complicated, despite the availability of newly approved kinase inhibitors. Various strategies to avoid the reduced efficacy of therapy have been explored, including...
19.
Vodicka P, Klener P, Trneny M
Onco Targets Ther
. 2022 Dec;
15:1481-1501.
PMID: 36510607
Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60-70% chance of cure with current R-CHOP chemoimmunotherapy. However, 30-40% of patients are refractory or relapsing. Many attempts failed...
20.
Obr A, Benesova K, Janikova A, Mocikova H, Belada D, Hruskova A, et al.
Ann Hematol
. 2022 Nov;
102(1):107-115.
PMID: 36369497
Ibrutinib revolutionized therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R/R MCL patients receiving ibrutinib with...